

# EAPM DRAFT AGENDA



European Alliance for  
Personalised Medicine

## ***EAPM Conference at ESMO***

***“The need for change – and how to make it happen  
: Defining the healthcare ecosystem to determine value”.***

***Friday, September 17th, 2021  
08.30 – 16.30 CET***

### **Overview**

The theme of EAPM's ninth annual event during the ESMO Congress will be “*The Need for Change: Defining the healthcare ecosystem to determine value.*” High-level speakers and attendees will come from a wide range of stakeholder groups including patients, healthcare professionals, academics, industry representatives, politicians and legislators, the media and more.

### **Issues Discussed:**

Since the opportunity clearly exists for input into EU thinking, what input should be made in the field of cancer? The most obvious need, given the current level of fragmentation of policy and practice, is for a new degree of coherence...

But coherence is not enough. A top-down imposition of new rules cannot be the answer if the essence of the EU's concern – the welfare of its citizens – is to have priority. The oft-cited mantra of patient-centred healthcare must also be given real meaning, and that implies a careful and thoughtful complement of bottom-up thinking too...

For both top-down and bottom-up strands to be brought successfully together, there must be a new degree of trust, too. The imposition of regulation and legislation cannot be the complete answer. It can create a more appropriate framework, but within that the promotion of innovation and of integration will always depend ultimately on voluntary cooperation.

All stakeholders will have to play their part in discussions and policy formation. And they will all have to accept that the ultimate objective is better health for patients. Their own interest and priorities must adapt to that priority.

For industry that could mean taking advantage of greater synergies in new models of clinical trials and drug development, making use of more sensitive and comprehensive data on delivery of therapeutic advantage - and with a more sophisticated relation between prices and demonstrated performance...

For health services it could mean more effective screening programmes ... using higher tech...low-dose radiation...

For institutions and member states it could mean more purposeful discussion – taking more account of input from stakeholders, avoiding repetition, and translating decisions into action...

In the Commission, the Council and the Parliament, it could mean closer links between their own internal departments and committees dealing with health, and closer links between all three of them in decision making.

## EAPM DRAFT AGENDA

For healthcare professionals it could mean openness to new ways of working, new techniques and technologies in screening, diagnosis and treatment, and a new focus on prevention – and readiness to undergo new training. For individual patients, this could mean new options for healthcare access – and new responsibilities for developing health literacy, so they too can play a bigger role in their own health and their treatment.

For Europe, beset by popular scepticism about politics, politicians and political systems, it could offer a powerful antidote to public hostility and populist disenchantment with technology and globalisation. At the level that matters most to everyone, their own personal interest, a recalibration of policy towards the patient could not only improve health, but restore faith in Europe itself.

This dynamics series of roundtable will look at different elements of this through the following sessions:

- Session I: Winning Stakeholders' Trust In Genomic Data Sharing and the use of Real World Evidence/Data
- Session II: Bringing Molecular Diagnostics into healthcare Systems
- Session III Regulating the future - Balance of patient safety and facilitating innovation – IVDR
- Session IV: 'Saving lives through Health Data collection and usage

### 08.30 – 10.45 **Session I: Winning Stakeholders' Trust in Genomic Data Sharing and the use of Real-World Data/Evidence**

This session will look at different aspects of the issue around the use of data in terms of Real World Evidence/Data

**Chair: Antoni Monserrat**, *Senior Expert on Cancer and rare Disease, DG SANTE*

### 08.30 – 09.20 **Setting the Scene for Public Health and keeping the person in personalised Healthcare.**

- **Cristian Busoi MEP**, *ENVI Committee, European Parliament (10 minutes)*
- **Christine Chomienne**, *Vice President, Cancer Mission Boards (10 Minutes) (Confirmed)*
- **Dipak Kalra**, *President, The European Institute for Innovation through Health Data (i~HD) (Confirmed)*
- **Françoise Bartoli**, *VP Head of Europe and Canada Oncology, AstraZeneca (confirmed)*

Q&A

### 09.20– 10.20 **Stakeholder Perspective**

#### **European Commission**

- **Ceri Thompson**, *Deputy Head of Unit, CNECT.H3 - eHealth, well-being, ageing, DG CONNECT, European Commission (TBC)*

#### EUnetHTA

- **Niklas Hedberg**, *Chief Pharmacist at the governmental authority, the Dental and Pharmaceuticals Benefits Agency (TLV), in Sweden. (10 Minutes) (Confirmed)*

#### UK

**Professor Sir Mark Caulfield**, *Former Chief Scientist, Genomics England(10 Minutes) (Confirmed)*

## EAPM DRAFT AGENDA

### Patient Expert Perspective

- **Bettina Ryll**, *Melanoma Patient Network Europe, Sweden.* ([Confirmed](#))

### European Reference Networks:

- **Birutė Tumiene**, *Vilnius University Hospital (10 Minutes)*

### **Discussion**

### Q&A

10.20 – 10.30 **Conclusion**

**BREAK**

## **10.45– 12.30 Session II: Bringing Molecular Diagnostics into healthcare Systems**

10.45– 11.00 **Setting the Scene**

- **Benedikt Westphalen**, *Koordinator Molekulare Onkologie, Comprehensive Cancer Centre, University of Munich* ([Confirmed](#))
- **Peter Liese**, *European People's Party, ENVI Committee, European Parliament*

11.00 – 12.15 **Country Perspective & European Union & Stakeholders**

#### **European Commission**

**Stefan Schreck**, *Head of unit for health programme and chronic diseases, DG SANTE, European Commission*  
([Confirmed](#))

#### **Slovenia**

- **Tanja Cufer**, *Professor of Oncology, Medical Faculty, University of Ljubljana (10 Minutes)*  
([Confirmed](#))

#### **Germany**

- **Olaf Rieß**, *University of Tübingen, Tübingen, Germany (10 Minutes)* ([Confirmed](#))

#### **Public Private Cooperation**

- Roche Speaker TBC (10 minutes)

#### **Ireland**

- **William Gallagher**, *University College Dublin, Dublin, Ireland* ([Confirmed](#))

12.15 – 12.30 **Conclusion**

**12.30– 13.30. Lunch**

## EAPM DRAFT AGENDA

### 13.30– 15.00 Session III: Regulating the future - Balance of patient safety and facilitating innovation - IVDR

This session will focus on the issues relating to the transposition of the IVDR and the impact on cancer diagnostics

#### 13.30 – 14.15 Setting the Scene

- **Olga Tkachenko**, DG for Health and Food Safety, European Commission
- **Monika Brüggemann**, Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. ([Confirmed](#))

#### 14.15 – 15.15 Stakeholder Perspective

##### France

- **Paul Hofman**, Head of the Laboratory of Clinical and Experimental Pathology at the University Hospital Nice, France ([Confirmed](#))

##### Spain

- **Federico Rojo**, Head of Pathology Department Fundacion Jimenez Diaz University Hospital Madrid, (10 Minutes)

##### Croatia

- **Eduard Vrdoljak**, Head of the Center for Oncology and Professor at the Faculty of Medicine at the University of Split.

##### Italy

- **Ettore Capoluongo**, University of Naples Federico II, Naples, Italy ([Confirmed](#))

Public Private Collaboration  
Novartis

#### Discussion

#### 15.15 – 15.30 Conclusion

### 15.30– 16.30 Session IV: 'Saving lives through Health Data collection and usage

This session will focus on the issues relating to a call to Action that Data Saves patients lives. Speaker include:

- **Birgit Bauer**, Patient Expert - Social Media & Digital Health Expert, Journalist, Speaker, Blogger ([Confirmed](#))
- **Tanja Spanic**, President, Europa Donna ([Confirmed](#))
- **Susanne Baars**, Sr. Global Thought Leadership Manager for expanding Precision Medicine, Siemens Healthineers ([Confirmed](#))
- **Zorana Maravic**, Acting CEO, Digestive Cancer Europe ([Confirmed](#))

#### 16.15 – 16.30 Conclusion

End of Conference

\*\*\*\*\*